Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 4,411 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 4,411 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $83.92, for a total value of $370,171.12. Following the transaction, the chief executive officer directly owned 2,180,000 shares of the company’s stock, valued at approximately $182,945,600. This trade represents a 0.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Price Performance

IRMD stock traded up $0.52 on Wednesday, reaching $85.27. 71,131 shares of the company traded hands, compared to its average volume of 86,931. iRadimed Corporation has a one year low of $50.88 and a one year high of $107.90. The company has a market cap of $1.09 billion, a P/E ratio of 46.60 and a beta of 0.90. The firm has a fifty day simple moving average of $94.77 and a 200-day simple moving average of $94.62.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The company had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, sell-side analysts forecast that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is 43.72%.

Institutional Trading of iRadimed

A number of institutional investors and hedge funds have recently modified their holdings of the business. First Trust Advisors LP bought a new stake in shares of iRadimed in the 1st quarter worth $225,000. Summit Global Investments grew its holdings in shares of iRadimed by 8.2% in the first quarter. Summit Global Investments now owns 7,661 shares of the medical equipment provider’s stock worth $737,000 after acquiring an additional 579 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of iRadimed by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after acquiring an additional 9,017 shares during the period. Principal Financial Group Inc. grew its holdings in shares of iRadimed by 14.7% in the first quarter. Principal Financial Group Inc. now owns 9,732 shares of the medical equipment provider’s stock worth $937,000 after acquiring an additional 1,245 shares during the period. Finally, Fifth Third Bancorp bought a new stake in shares of iRadimed in the first quarter worth $198,000. Institutional investors own 92.34% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Lake Street Capital reissued a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Freedom Capital raised iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings raised iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Finally, Roth Mkm reissued a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.